Ray Dalio's TEVA Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 864.8K shares of Teva Pharmaceutical Industries Limited (TEVA) worth $17.47 M, representing 0.07% of the portfolio. First purchased in 2015-Q4, this long-term strategic position has been held for 40 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in TEVA, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 855.4K shares. Largest reduction occurred in Q4 2022, reducing 134.8K shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Teva Pharmaceutical Industries Limited (TEVA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Teva Pharmaceutical Industries Limited (TEVA) Trades by Ray Dalio
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2015 | +24,100 | New Buy | 24,100 | $65.64 |
| Q1 2016 | +600 | Add 2.49% | 24,700 | $53.52 |
| Q2 2017 | +3,000 | Add 12.15% | 27,700 | $33.21 |
| Q1 2018 | -6,500 | Reduce 23.47% | 21,200 | $17.08 |
| Q3 2018 | +2,400 | Add 11.32% | 23,600 | $21.53 |
| Q4 2018 | -23,600 | Sold Out | 23,600 | $0.00 |
| Q2 2021 | +241,669 | New Buy | 241,669 | $9.90 |
| Q3 2021 | +33,548 | Add 13.88% | 275,217 | $9.74 |
| Q4 2021 | +244,402 | Add 88.80% | 519,619 | $8.01 |
| Q1 2022 | +21,895 | Add 4.21% | 541,514 | $9.39 |
| Q2 2022 | -56,471 | Reduce 10.43% | 485,043 | $7.52 |
| Q3 2022 | -40,785 | Reduce 8.41% | 444,258 | $8.07 |
| Q4 2022 | -134,841 | Reduce 30.35% | 309,417 | $9.12 |
| Q1 2023 | -66,770 | Reduce 21.58% | 242,647 | $8.85 |
| Q2 2023 | -10,137 | Reduce 4.18% | 232,510 | $7.53 |
| Q3 2023 | -37,985 | Reduce 16.34% | 194,525 | $10.20 |
| Q4 2023 | -121,451 | Reduce 62.43% | 73,074 | $10.44 |
| Q1 2024 | -26,413 | Reduce 36.15% | 46,661 | $14.11 |
| Q2 2024 | -24,583 | Reduce 52.68% | 22,078 | $16.25 |
| Q3 2024 | +1,144 | Add 5.18% | 23,222 | $18.02 |
| Q4 2024 | -13,829 | Reduce 59.55% | 9,393 | $22.04 |
| Q1 2025 | -9,393 | Sold Out | 9,393 | $0.00 |
| Q3 2025 | +864,782 | New Buy | 864,782 | $20.20 |
Ray Dalio's Teva Pharmaceutical Industries Limited Investment FAQs
Ray Dalio first purchased Teva Pharmaceutical Industries Limited (TEVA) in Q4 2015, acquiring 24,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Teva Pharmaceutical Industries Limited (TEVA) for 40 quarters since Q4 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's largest addition to Teva Pharmaceutical Industries Limited (TEVA) was in Q3 2025, adding 864,782 shares worth $17.47 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 864,782 shares of Teva Pharmaceutical Industries Limited (TEVA), valued at approximately $17.47 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Teva Pharmaceutical Industries Limited (TEVA) represents approximately 0.07% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's peak holding in Teva Pharmaceutical Industries Limited (TEVA) was 864,782 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.